Target intelligence / Profile preview

Shieldin complex subunit 2 (SHLD2)

Target
SHLD2
Molecular classification
Other (component of a DNA repair complex/protein complex, not a classical receptor, enzyme, transporter, etc.), DNA repair protein
01

Overview

Shieldin complex subunit 2 (SHLD2) is a core component of the shieldin complex, which also includes SHLD1, SHLD3, and REV7. The complex acts downstream of 53BP1–RIF1 in DNA double-strand break repair, suppressing end resection and favoring repair via the non-homologous end joining (NHEJ) pathway while inhibiting homologous recombination. SHLD2 possesses a critical N-terminal domain necessary for its recruitment to DNA breaks and a C-terminal OB-fold domain capable of direct DNA binding. Shieldin, through its DNA end-protection activity, is crucial for immunoglobulin class-switch recombination, telomere fusion, and genome integrity. Loss of SHLD2 function shifts DNA repair toward homologous recombination and can confer resistance or sensitivity to DNA-damaging therapies such as PARP inhibitors, making it of interest in BRCA1-deficient cancers.

Other names
FAM35ARINN2MGC5560bA163M19.1FAM35A1Protein FAM35ARINN1-REV7-interacting novel NHEJ regulator 2Shield complex subunit 2family with sequence similarity 35 member A
02

Mechanism of action

No known direct-drug interactions; modulators targeting SHLD2 would likely influence DNA repair pathway usage (e.g., promote sensitivity to PARP inhibitors via synthetic lethality when SHLD2 is lost)

03

Biological functions

DNA double-strand break repairRegulation of DNA repair pathway choice (homologous recombination vs. non-homologous end joining)Negative regulation of homologous recombinationPositive regulation of non-homologous end joiningPositive regulation of isotype switching in immunoglobulins
04

Disease associations

Cancer (notably hereditary breast and ovarian cancer syndromes)Possibly other diseases related to DNA repair defects (e.g. Dystonia 6, Torsion)
05

Safety considerations

Potential for genomic instability (increased mutagenesis and cancer risk) if SHLD2 or shieldin are inhibited or genetically lost, due to DNA repair pathway dysregulation
06

Biomarkers

SHLD2 loss-of-function (or shieldin complex defects) is being investigated as a potential biomarker for response to PARP inhibitors in BRCA1-deficient cancers

Beyond the preview

Go deeper on Shieldin complex subunit 2 (SHLD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shieldin complex subunit 2 (SHLD2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call